Xiang Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Xiang Gao has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Rui Lin
Institute of Clinical Medicine, Zhanjiang Central Hospital, Guangdong Medical University (Central People’s Hospital of Zhanjiang), Zhanjiang, 524045, People’s Republic of China
2 shared publications - Yanzhi Liu
Key Laboratory of Traditional Chinese Medicine for the Prevention and Treatment of Infectious Diseases, Institute of Clinical Medicine, Zhanjiang Central Hospital, Guangdong Medical University (Central People’s Hospital of Zhanjiang), Zhanjiang, Guangdong, 524045, China
2 shared publications - Bilian Xu
Marine Medical Research Institute of Zhanjiang, School of Ocean and Tropical Medicine, Guangdong Medical University, Zhanjiang City, Guangdong Province, 524023, People's Republic of China
1 shared publication - Chenlin Tu
Stem Cell Research and Cellular Therapy Center
1 shared publication Dahong Liang
Key Laboratory of Traditional Chinese Medicine for the Prevention and Treatment of Infectious Diseases, Zhanjiang Central Hospital, Guangdong Medical University, Zhanjiang City, Guangdong Province, 524045, People's Republic of China
1 shared publicationFan Gong
1 shared publication
Latest Publications
- Open Access
- 1 May 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-16
DAPT Mitigates Osteoarthritic Cartilage Degeneration and Enhances Articular Repair Through Targeted Modulation of the Gucy1a3 and Notch Signaling Axis
Background: While Nitric oxide (NO) and Notch signaling pathways are implicated in osteoarthritis (OA) progression, their functional interplay remains largely unexplored. We hypothesized that Gucy1a3 (sGCα 1) functions as a non-canonical soluble sensor, bridging nitrosative stress to pathological Notch activation. Methods: To test the hypothesis that Gucy1a3 mediates NO-Notch crosstalk, we used both sodium nitroprusside (SNP)-stimulated chondrocytes and a rat medial meniscus resection model. Mechanistic hierarchy was analyzed via Gucy1a3 siRNA knockdown and the Notch inhibitor DAPT. Additionally, the capacity of DAPT to modulate chondrogenic lineage commitment was evaluated in rat bone marrow mesenchymal stem cells (BMSCs). Results: DAPT reversed SNP-induced catabolism in chondrocytes, suppressing Notch components (Notch1, Jagged1) and inflammatory markers (iNOS, MMP13) while restoring anabolic gene expression. Crucially, DAPT suppressed Gucy1a3 expression, breaking a reciprocal positive feedback loop (NO-Gucy1a3-Notch). Although Gucy1a3 knockdown phenocopied the anti-inflammatory signature of DAPT, DAPT uniquely activated the chondrogenic differentiation of BMSCs. In preclinical models, intra-articular delivery of DAPT effectively safeguarded joint homeostasis by reducing subchondral bone deterioration and decreasing cartilage degeneration. Conclusion: This study identifies Gucy1a3 as a mediator that transduces inflammatory nitric oxide signals to activate Notch. DAPT exerts therapeutic effects by inhibiting Gucy1a3-mediated catabolism in chondrocytes and promoting the differentiation of BMSCs. Although these findings are currently limited to in vitro and rodent models, targeting this signaling axis offers a potential strategy for developing disease-modifying osteoarthritis drugs. The illustration compares pathological and therapeutic pathways in cartilage treatment. On the left, the pathological pathway shows activation of Gucy1a3 by nitric oxide, leading to increased catabolic markers (iNOS, MMP13) and decreased anabolic markers (Aggrecan, Col2a1) in the nucleus. On the right, the therapeutic pathway involves DAPT and siRNA inhibiting Gucy1a3, resulting in increased anabolic markers and decreased catabolic markers. Bone marrow-derived stem cells (BMSCs) treated with DAPT form cartilage globules. Below, two knee joint illustrations compare osteoarthritis (OA) untreated and treated with DAPT, showing improved cartilage in the treated joint.Illustration of pathological vs. therapeutic pathways in cartilage treatment using DAPT and siRNA.
- 1 May 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-16
Open AccessDAPT Mitigates Osteoarthritic Cartilage Degeneration and Enhances Articular Repair Through Targeted Modulation of the Gucy1a3 and Notch Signaling Axis
Background: While Nitric oxide (NO) and Notch signaling pathways are implicated in osteoarthritis (OA) progression, their functional interplay remains largely unexplored. We hypothesized that Gucy1a3 (sGCα 1) functions as a non-canonical soluble sensor, bridging nitrosative stress to pathological Notch activation. Methods: To test the hypothesis that Gucy1a3 mediates NO-Notch crosstalk, we used both sodium nitroprusside (SNP)-stimulated chondrocytes and a rat medial meniscus resection model. Mechanistic hierarchy was analyzed via Gucy1a3 siRNA knockdown and the Notch inhibitor DAPT. Additionally, the capacity of DAPT to modulate chondrogenic lineage commitment was evaluated in rat bone marrow mesenchymal stem cells (BMSCs). Results: DAPT reversed SNP-induced catabolism in chondrocytes, suppressing Notch components (Notch1, Jagged1) and inflammatory markers (iNOS, MMP13) while restoring anabolic gene expression. Crucially, DAPT suppressed Gucy1a3 expression, breaking a reciprocal positive feedback loop (NO-Gucy1a3-Notch). Although Gucy1a3 knockdown phenocopied the anti-inflammatory signature of DAPT, DAPT uniquely activated the chondrogenic differentiation of BMSCs. In preclinical models, intra-articular delivery of DAPT effectively safeguarded joint homeostasis by reducing subchondral bone deterioration and decreasing cartilage degeneration. Conclusion: This study identifies Gucy1a3 as a mediator that transduces inflammatory nitric oxide signals to activate Notch. DAPT exerts therapeutic effects by inhibiting Gucy1a3-mediated catabolism in chondrocytes and promoting the differentiation of BMSCs. Although these findings are currently limited to in vitro and rodent models, targeting this signaling axis offers a potential strategy for developing disease-modifying osteoarthritis drugs. The illustration compares pathological and therapeutic pathways in cartilage treatment. On the left, the pathological pathway shows activation of Gucy1a3 by nitric oxide, leading to increased catabolic markers (iNOS, MMP13) and decreased anabolic markers (Aggrecan, Col2a1) in the nucleus. On the right, the therapeutic pathway involves DAPT and siRNA inhibiting Gucy1a3, resulting in increased anabolic markers and decreased catabolic markers. Bone marrow-derived stem cells (BMSCs) treated with DAPT form cartilage globules. Below, two knee joint illustrations compare osteoarthritis (OA) untreated and treated with DAPT, showing improved cartilage in the treated joint.Illustration of pathological vs. therapeutic pathways in cartilage treatment using DAPT and siRNA.
- Open Access
- 8 July 2025
- Vol. 19, 5855-5870
Vitamin D Alleviates Osteoarthritis Progression by Targeting Cartilage and Subchondral Bone via Myd88-TAK1-ERK Axis Suppression
Osteoarthritis (OA) causes irreversible joint damage, but current treatments fail to fully address its complex pathology. Emerging evidence suggests subchondral bone metabolic dysfunction may initiate OA. While vitamin D (VitD) is well-established for bone metabolism regulation in osteoporosis, its therapeutic potential in OA remains unclear despite observational studies suggesting protective effects. Our integrated in vivo/in vitro study demonstrates VitD’s dual chondroprotective and osteogenic actions in OA. Sprague-Dawley rats (n=24) were divided into three groups: sham operation (Sham), OA model (OA), and OA+VitD treatment, with 8 rats in each group. Oral cholecalciferol (2.34 μg/kg/day) was administered for 6 weeks post-Monosodium iodoacetate (MIA) induction. The therapeutic potential of vitamin D was evaluated through a series of in vivo experiments. Human chondrocyte C28 cells were pretreated with TNFα (1ng/mL) to model inflammatory injury, followed by 1,25(OH)2 D3 (10−2 μM) exposure for 72 hours to assess the VitD’s effects of chondrogenesis and further investigate its underlying mechanism. In OA rats, VitD suppressed femoral cartilage degradation (evidenced by 567.76% increased cartilage area, and 39.13% decreased Osteoarthritis Cartilage Histopathology (OACH) score and enhanced subchondral bone mass (61.81% higher BV/TV). At the molecular level, VitD downregulated the expression of cartilage matrix metalloproteinase 13 (MMP13), with a reduction of 74.72% compared to OA group. Additionally, VitD inhibit inflammatory signaling pathways, particularly through the MyD88-TAK1-ERK axis in chondrocytes, and decrease serum IL-6 level. Mechanistic validation of these findings was demonstrated by protein expression reduction of Myd88 (31.22%), phospho-ERK1/2 (66.11%), AP-1 (61.43%) and NFκB (34.36%) compared to OA group. In vitro, VitD also rescued ethanol-induced C28 cell viability loss while significantly upregulating cartilage anabolic markers. These findings establish VitD as a multimodal OA therapeutic agent targeting both cartilage catabolism and subchondral bone remodeling through Myd88-TAK1-ERK axis.
- 8 July 2025
- Vol. 19, 5855-5870
Open AccessVitamin D Alleviates Osteoarthritis Progression by Targeting Cartilage and Subchondral Bone via Myd88-TAK1-ERK Axis Suppression
Osteoarthritis (OA) causes irreversible joint damage, but current treatments fail to fully address its complex pathology. Emerging evidence suggests subchondral bone metabolic dysfunction may initiate OA. While vitamin D (VitD) is well-established for bone metabolism regulation in osteoporosis, its therapeutic potential in OA remains unclear despite observational studies suggesting protective effects. Our integrated in vivo/in vitro study demonstrates VitD’s dual chondroprotective and osteogenic actions in OA. Sprague-Dawley rats (n=24) were divided into three groups: sham operation (Sham), OA model (OA), and OA+VitD treatment, with 8 rats in each group. Oral cholecalciferol (2.34 μg/kg/day) was administered for 6 weeks post-Monosodium iodoacetate (MIA) induction. The therapeutic potential of vitamin D was evaluated through a series of in vivo experiments. Human chondrocyte C28 cells were pretreated with TNFα (1ng/mL) to model inflammatory injury, followed by 1,25(OH)2 D3 (10−2 μM) exposure for 72 hours to assess the VitD’s effects of chondrogenesis and further investigate its underlying mechanism. In OA rats, VitD suppressed femoral cartilage degradation (evidenced by 567.76% increased cartilage area, and 39.13% decreased Osteoarthritis Cartilage Histopathology (OACH) score and enhanced subchondral bone mass (61.81% higher BV/TV). At the molecular level, VitD downregulated the expression of cartilage matrix metalloproteinase 13 (MMP13), with a reduction of 74.72% compared to OA group. Additionally, VitD inhibit inflammatory signaling pathways, particularly through the MyD88-TAK1-ERK axis in chondrocytes, and decrease serum IL-6 level. Mechanistic validation of these findings was demonstrated by protein expression reduction of Myd88 (31.22%), phospho-ERK1/2 (66.11%), AP-1 (61.43%) and NFκB (34.36%) compared to OA group. In vitro, VitD also rescued ethanol-induced C28 cell viability loss while significantly upregulating cartilage anabolic markers. These findings establish VitD as a multimodal OA therapeutic agent targeting both cartilage catabolism and subchondral bone remodeling through Myd88-TAK1-ERK axis.